samedan logo
 
 
spacer
home > pmps > autumn 2002 > parallel sales and counterfeit products - answers for the pharmaceutical industry
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Parallel Sales and Counterfeit Products - Answers for the Pharmaceutical Industry

Trouble on the Horizon

With the continued increase in counterfeit and diverted products, many industries are faced with a serious threat to sales profitability and trademark value. The cost of counterfeit goods accounts for nearly US$280 billion annually, while this figure could increase several times over to account for diverted products, gray markets and illegal transit goods.

An Industry Challenge

Product counterfeiting is a massive growth industry, supplying fake goods and redirecting products. New printing and packaging methods have made it cheaper and quicker to replicate the look and feel of products, while the Internet has provided the perfect tool to reach untapped markets and dump products cost-effectively. These problems impact many industries, but it is pharmaceuticals that face the most serious consequences, over and above lost profitability:
Consumer health and safety
Company reputation and trust
Potential liability and negligence claims


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Stephen Polinsky, Pharmaceutical Practice Leader at GenuOne, Inc.
Stephen Polinsky co-founded GenuOne and has been instrumental in developing their comprehensive brand security system.

Prior to co-founding GenuOne, Stephen held positions as a Business Development Manager for Philips Electronics, managing trade channels for voice recognition products, and sales and marketing positions at NORTEL. Stephen earned a Bachelor of Arts from the University of Hartford.

spacer
Stephen Polinsky
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Small Scale Biomanufacturing – clinical trials, cell & gene therapies

18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol

This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >>

 
News and Press Releases

Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement